NATCO Pharma Revenue and Competitors
Estimated Revenue & Valuation
- NATCO Pharma's estimated annual revenue is currently $174.7M per year.
- NATCO Pharma's estimated revenue per employee is $201,000
Employee Data
- NATCO Pharma has 869 Employees.
- NATCO Pharma grew their employee count by -10% last year.
NATCO Pharma's People
Name | Title | Email/Phone |
---|
NATCO Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is NATCO Pharma?
Natco Pharma Limited - India is a pharmaceuticals company based out of India.
keywords:N/AN/A
Total Funding
869
Number of Employees
$174.7M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NATCO Pharma News
2022-04-20 - Pomalidomide Market Size, Outlook And Forecast | Celgene, Natco ...
Celgene, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical,...
2022-04-20 - Glatiramer Market Size 2022-2029| Key Players Teva, NATCO ...
Glatiramer Market Size 2022-2029| Key Players Teva, NATCO Pharma, Mylan, Novartis. Market Size And Forecast. New Jersey, USA,- The research study...
2022-03-30 - Natco Pharma Ltd continues to edge higher
The stock is down 0.74% in last one year as compared to a 22.63% jump in NIFTY and a 10.4% jump in the Nifty Pharma index. Natco Pharma Ltd is...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $35M | 869 | 5% | N/A |
#2 | $182.5M | 869 | 3% | N/A |
#3 | $75M | 870 | 2% | N/A |
#4 | $329.2M | 871 | 8% | N/A |
#5 | $118700M | 871 | -9% | N/A |